In managing non-renal SLE, how do you approach choosing between belimumab and anifrolumab?
Is there a role for cytokine profiling to assess the involvement of adaptive versus innate immune pathways?
Can genetic testing or epigenetic markers—such as methylation or hypomethylation of interferon-regulated genes—inform treatment decisions?
Lastly, is there clinical utility in integrating cytokine panels with validated lupus activity markers (e.g., anti-dsDNA, anti-Smith antibodies, complement levels) as part of a precision medicine strategy in routine practice?
Community PollStarted
What factors help you decide between belimumab and anifrolumab for managing non-renal SLE?
57 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Rheumatology · Uniformed Services University of the Health Sciences (USUHS)
Answered on · Updated on
Dr. @Dr. First Last, You are asking what we are all dreaming of... personalized medicine where we could identify a patient's immunologic endotype and better choose disease-modifying drugs rather than cycling patients from one combination of drugs to another.
Right now, it is a dream. With so many bio...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Rheumatology · University of Alabama Birmingham
Answered on
This is a complex but important question, and I typically begin by clarifying the organ system involved, the severity of disease, previous treatment history—particularly any failure of conventional DMARDs—and the current steroid burden, as this greatly influences the choice of biologic.
1. Choosing ...
Join for free or sign in to see the full answer